UCB: new pilot plant in Belgium
Enlarge image


UCB: new pilot plant in Belgium

18.09.2012 - UCB S.A. has officially opened the doors to a new pilot biotech plant at its Braine-L'Alleud site in Belgium.

The Brussels-based drugmaker has invested more than €65m into the project, which was supported by the Walloon region. The 5,100 square meter facility is currently undergoing a validation phase. After becoming fully operational in the course of 2013, the first four bioreactors with a total volume of 3,200 litres will start to produce cell culture-based therapeutic proteins for UCB’s research pipeline and clinical trials. At the same time, manufacturing processes will be designed and optimised to move from development to full scale industrial production. The facility will include integrated laboratories and additional infrastructure to house 100 staff.

“Today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline“, stated Roch Doliveux, CEO of UCB. “With this bio pilot plant, we can more rapidly initiate clinical studies of new antibody-based therapeutics that are addressing serious unmet medical needs.”

 UCB is currently heavily investing to push its production capabilities. Just last year, the Belgian company also initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland. The new manufacturing unit is expected to become operational in 2015 and requires an investment of €250m.



12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK40.4%
  • ZEALAND PHARMA (DK)160.00 DKK31.1%
  • THROMBOGENICS (B)3.98 EUR30.1%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5137.5%
  • CHRONTECH PHARMA (S)0.34 SEK466.7%
  • GALAPAGOS (B)38.68 EUR247.8%


  • NEOVACS (F)0.75 EUR-76.1%
  • BIOTEST (D)19.54 EUR-72.9%
  • EVOCUTIS (UK)0.15 GBP-68.7%

No liability assumed, Date: 12.10.2015